Table 1.
Baseline patient characteristics
| All (N = 836) | France (N = 269) | Germany (N = 213) | Italy (N = 136) | UK (N = 218) | P value | |
|---|---|---|---|---|---|---|
| Age, n (%) | ||||||
| Median | 73.0 | 70.0 | 74.0 | 73.0 | 73.0 | <.001 |
| <65 y | 84 (10) | 56 (21) | 2 (1) | 2 (1) | 24 (11) | <.001 |
| 65‐74 y | 453 (54) | 152 (57) | 120 (56) | 80 (59) | 101 (46) | |
| 75+ y | 299 (36) | 61 (23) | 91 (43) | 54 (40) | 93 (43) | |
| Gender, n (%) | ||||||
| Male | 511 (61) | 163 (61) | 142 (67) | 70 (51) | 136 (62) | .041 |
| Female | 325 (39) | 106 (39) | 71 (33) | 66 (49) | 82 (38) | |
| ECOG PS, n (%) | ||||||
| 0 | 46 (6) | 10 (4) | 4 (2) | 16 (12) | 16 (7) | <.001 |
| 1 | 383 (46) | 153 (57) | 103 (48) | 19 (14) | 108 (50) | |
| 2 | 263 (31) | 78 (29) | 90 (42) | 19 (14) | 76 (35) | |
| 3 | 57 (7) | 22 (8) | 12 (6) | 5 (4) | 18 (8) | |
| 4 | 9 (1) | 2 (1) | 4 (2) | 3 (2) | 0 (0) | |
| Unknown | 78 (9) | 4 (1) | 0 (0) | 74 (54) | 0 (0) | |
| Frailty status, n (%) | ||||||
| Fit | 130 (16) | 93 (35) | 10 (5) | 7 (5) | 20 (9) | <.001 |
| Intermediate fitness | 427 (51) | 123 (46) | 163 (77) | 25 (18) | 116 (53) | |
| Frail | 218 (26) | 53 (20) | 39 (18) | 51 (38) | 75 (34) | |
| Unknown | 61 (7) | 0 (0) | 1 (0) | 53 (39) | 7 (3) | |
| CCI, n (%) | ||||||
| 0 | 231 (28) | 108 (40) | 32 (15) | 50 (37) | 41 (19) | <.001 |
| 1 | 204 (24) | 68 (25) | 63 (30) | 23 (17) | 50 (23) | |
| 2+ | 368 (44) | 81 (30) | 114 (54) | 53 (39) | 120 (55) | |
| Unknown | 33 (4) | 12 (4) | 4 (2) | 10 (7) | 7 (3) | |
| ISS Stage, n (%) | ||||||
| Stage I | 85 (10) | 36 (13) | 15 (7) | 13 (10) | 21 (10) | <.001 |
| Stage II | 170 (20) | 78 (29) | 24 (11) | 22 (16) | 46 (21) | |
| Stage III | 469 (56) | 128 (48) | 170 (80) | 43 (32) | 128 (59) | |
| Unknown | 112 (13) | 27 (10) | 4 (2) | 58 (43) | 23 (11) | |
| Immunoglobulin class, n (%) | ||||||
| IgG | 432 (52) | 139 (52) | 134 (63) | 68 (50) | 91 (42) | <.001 |
| IgA | 153 (18) | 42 (16) | 36 (17) | 31 (23) | 44 (20) | |
| Light chain only | 106 (13) | 23 (9) | 27 (13) | 19 (14) | 37 (17) | |
| IgM | 14 (2) | 8 (3) | 6 (3) | 0 (0) | 0 (0) | |
| IgE | 10 (1) | 5 (2) | 3 (1) | 0 (0) | 2 (1) | |
| IgD | 6 (1) | 4 (1) | 2 (1) | 0 (0) | 0 (0) | |
| Other a | 2 (0) | 0 (0) | 0 (0) | 2 (1) | 0 (0) | |
| Biclonal | 1 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0) | |
| Unknown/not documented | 112 (13) | 48 (18) | 5 (2) | 16 (12) | 43 (20) | |
| Extramedullary disease, n (%) | 90 (11) | 35 (13) | 19 (9) | 10 (7) | 26 (12) | .249 |
| CRAB symptoms, n (%) | 750 (90) | 249 (93) | 208 (98) | 113 (83) | 180 (83) | <.001 |
| Renal insufficiency | 133 (16) | 46 (17) | 40 (19) | 17 (13) | 30 (14) | .317 |
| Hypercalcemia | 119 (14) | 55 (20) | 24 (11) | 4 (3) | 36 (17) | <.001 |
| Anemia | 362 (43) | 120 (45) | 71 (33) | 50 (37) | 121 (56) | <.001 |
| Bone lesions | 643 (77) | 216 (80) | 197 (92) | 90 (66) | 140 (64) | <.001 |
| Cytogenetic testing done, n (%) | 210 (25) | 113 (42) | 25 (12) | 31 (23) | 41 (19) | <.001 |
| High risk | 51 (6) | 27 (10) | 6 (3) | 6 (4) | 12 (6) | <.001 |
| Standard risk | 159 (19) | 86 (32) | 19 (9) | 25 (18) | 29 (13) | |
| Unknown risk | 626 (75) | 156 (58) | 188 (88) | 105 (77) | 177 (81) | |
| Follow‐up duration from NDMM diagnosis in months, Median (IQR) | 20.9 (14.0 to 49.9) | 20.9 (8.0 to 44.3) | 18.9 (18.9 to 18.9) | 21.2 (15.2 to 53.8) | 56.5 (10.1 to 62.0) | |
a
Other Ig class includes Bence Jones/lambda, multi‐molecular MM. Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; ISS, international staging system; UK, United Kingdom